

**Meeting Minutes**  
**North Dakota Medicaid Drug Use Review (DUR) Board**  
**Meeting Date: June 3, 2026**  
**Time and Location: 1:00 pm CST in Bismarck, North Dakota**

**Call to Order:**

A regular quarterly meeting of the North Dakota Medicaid Drug Use Review (DUR) Board meeting was convened at 1:02 pm CST with K. Martian presiding as Presiding Officer. DUR Board Coordinator, J. McKee recording minutes.

**Roll Call:**

**Board Members Voting:**

Present: Stephanie Antony, Gabriela Balf, Amanda Dahl, Kurt Datz, Andrea Honeyman, Laura Kroetsch, Kevin Martian, Paige Adkins, Jessica Ziegler, Amy Werremeyer

Absent: Kristen Peterson, Matthew Zimny

Quorum Present: Yes

**Board Members Non-Voting:**

Absent: Kathleen Traylor

**Medicaid Pharmacy Department:**

Present: Jeff Hostetter, Brendan Joyce, Alexi Murphy, LeNeika Roerich, Katie Steig

Absent:

**Approval of Meeting Minutes:**

Motion: Moved by K. Datz to approve the minutes of the March 4, 2026, meeting, motion was seconded by A. Honeyman. Motion carried.

The minutes of the March 4, 2026, meeting were approved as distributed.

**Reports:**

**Administrative Report: K. Steig**

K. Steig shared with the Board Cost of Dispensing Survey, Acentra NDMA Website Overview

**Financial Report: B. Joyce**

B. Joyce shared with the Board trends of reimbursement amount vs net spend for pharmacy drug claims. This information can be found in the handout.

**Financial Report: Top Drugs provided by B. Joyce**

B. Joyce presented the quarterly review of the top 25 drugs based on total number and cost of claims and the top 15 therapeutic classes based on number and cost of claims. This report can be found in the handout.

**Retrospective Drug Utilization Review (RDUR) Report by J. McKee**

J. McKee reviewed the quarterly RDUR criteria that were selected for review of each month and information from a targeted mailing. This material can be found in the handout.

**Clinical Report: Prior Authorization and Criteria Updates by J. McKee**

J. McKee presented prior authorization and criteria updates with emphasis on the following sections in the PDL: Alzheimer's Disease, Heart Failure, Imcivree, and Mounjaro.

Special Orders: Elections completed for Presiding Officer and Vice Presiding Officer

K. Martian nominated K. Datz for Vice Presiding Officer. A. Werremeyer seconded. K. Datz re-elected as Vice Presiding Officer.

K. Martian nominated K. Martian for Presiding Officer. A. Werremeyer seconded. K. Martian re-elected as Presiding Officer.

Unfinished Business:

K. Steigh presented updated information for Aqvesme, Ozempic for Type 1 Diabetes and chronic kidney disease, Leqembi renewal criteria, Sapropterin non-responsive after 1 month at 20 mg/kg.

New business:

Second Reviews presented by J. McKee

J. McKee presented group prior authorization criteria for Acromegaly

Motion: Moved by K. Martian to place Acromegaly on prior authorization, motion was seconded by K. Datz. Motion carried.

J. McKee presented group prior authorization criteria for Calcium-Channel Blockers

Motion: Moved by K. Datz to place Calcium-Channel Blockers on prior authorization, motion was seconded by K. Martian. Motion carried.

J. McKee presented group prior authorization criteria for Graft vs. Host Disease

Motion: Moved by K. Martian to place Graft vs. Host Disease on prior authorization, motion was seconded by A. Werremeyer. Motion carried with change to add specialist treating disease to the criteria.

J. McKee presented group prior authorization criteria for Malaria

Motion: Moved by K. Datz to place Malaria on prior authorization, motion was seconded by A. Dahl. Motion carried.

First Reviews presented by J. McKee

J. McKee presented an overview of Familial Chylomicronemia Syndrome (FCS). The presented material can be found in the handout.

Motion: Moved by K. Martian to draft prior authorization for Familial Chylomicronemia Syndrome (FCS), motion was seconded by K. Datz. Motion carried.

First Reviews presented by J. McKee

J. McKee presented an overview of Nausea and Vomiting. The presented material can be found in the handout.

Motion: Moved by K. Martian to draft prior authorization for Nausea and Vomiting, motion was seconded by A. Werremeyer. Motion carried.

First Reviews presented by J. McKee

J. McKee presented an overview of Thrombotic Microangiopathies (TMA). The presented material can be found in the handout.

Motion: Moved by K. Martian to draft prior authorization for Thrombotic Microangiopathies (TMA), motion was seconded by K. Datz. Motion carried.

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations:  
RDUR criteria recommendations were reviewed. The presented material can be found in the handout.

Motion: Moved by K. Datz to approve the RDUR criteria, motion was seconded by K. Martian. Motion carried.

Announcements:

Next meeting is September 2, 2026.

Adjournment:

Meeting adjourned by K. Martian at 2:17 pm CST.

Date of Minutes Approval:

Minutes submitted by: Julie McKee, Acentra Health